HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Cholesterol Drugs Preferred Over Supplements, NCL Survey Finds

This article was originally published in The Tan Sheet

Executive Summary

Consumers would use OTC cholesterol-lowering drugs instead of dietary supplements currently marketed as maintaining healthy cholesterol levels, a survey conducted by the National Consumers League finds.

You may also be interested in...



National Consumers League OTC Label Comprehension Web Site Goes Live

A Web site aimed at helping consumers better understand over-the-counter drug labeling launched Sept. 27 as part of a nationwide National Consumers League effort to teach and reinforce the importance of reading and comprehending OTC labeling.

Cholesterol Claim Clarification To Be Covered In Upcoming FDA Guidance

"Inconsistencies" in FDA's handling of "philosophically-related" cholesterol claims will be addressed in the agency's upcoming guidance on dietary supplement structure/function claims, the Center for Food Safety & Applied Nutrition's Robert Moore, PhD, told a FDLI meeting on supplement regulation in Washington, D.C. June 26.

Rx-To-OTC Switch Flips On With June Public Forum, July NDAC Meeting

The suitability of specific Rx drug classes - such as antihypertensive agents, osteoporosis treatments and oral contraceptives - for OTC use will be examined by FDA at a June 28-29 meeting in Gaithersburg, Md.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel